Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1.2K |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine | 2017 | 1.1K |
Association analysis identifies 65 new breast cancer risk loci | Nature | 2017 | 643 |
Intertumoral Heterogeneity within Medulloblastoma Subgroups | Cancer Cell | 2017 | 511 |
Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Lancet Oncology, The | 2017 | 275 |
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles | Cell Reports | 2017 | 247 |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study | Journal of Clinical Oncology | 2017 | 246 |
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL | Blood | 2017 | 244 |
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease | Blood | 2017 | 234 |
A novel community driven software for functional enrichment analysis of extracellular vesicles data | Journal of Extracellular Vesicles | 2017 | 200 |
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies | JAMA Neurology | 2017 | 179 |
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer | Clinical Cancer Research | 2017 | 160 |
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors | Pancreas | 2017 | 152 |
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer | JAMA Oncology | 2017 | 152 |
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer | Journal of the National Cancer Institute | 2017 | 138 |
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial | Lancet Haematology,the | 2017 | 137 |
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States | Blood | 2017 | 134 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms | Journal of Clinical Endocrinology and Metabolism | 2017 | 125 |
Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast Cancer | Clinical Cancer Research | 2017 | 119 |
Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee | International Journal of Radiation Oncology Biology Physics | 2017 | 111 |
Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution | Surgical Endoscopy and Other Interventional Techniques | 2017 | 103 |
A conserved NAD binding pocket that regulates protein-protein interactions during aging | Science | 2017 | 102 |
Genomic Profiling of Small-Bowel Adenocarcinoma | JAMA Oncology | 2017 | 101 |
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide | Blood | 2017 | 101 |
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α | Clinical Cancer Research | 2017 | 101 |